Appropriations and report language as it relates to compounding pharmacy.
Issues related to the NASEM report to the FDA on compounding bioidentical hormones. Issues related to the MOU under 503A of the FDCA.
Issues related to the federal regulation of compounding pharmacy. No specific legislation at this time.
Duration: April 16, 2013
to
June 30, 2021
General Issues: Budget/Appropriations , Health Issues , Pharmacy , Law Enforcement/Crime/Criminal Justice , Medical/Disease Research/Clinical Labs
Spending: about $369,325 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2013: U.S. Senate, House of Representatives, Food & Drug Administration (FDA)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
James Rock
Staff Asst, US House Committee on Budget - 1985 to 2000
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2021
Rock & Associates terminated an engagement in which they represented Women's International Pharmacy on Oct. 9, 2021.
Original Filing: 301297543.xml
Lobbying Issues
Appropriations and report language as it relates to compounding pharmacy.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the NASEM report to the FDA on compounding bioidentical hormones. Issues related to the MOU under 503A of the FDCA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the federal regulation of compounding pharmacy. No specific legislation at this time.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
1st Quarter, 2021
In Q1, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on May 4, 2021.
Original Filing: 301270342.xml
Lobbying Issues
Appropriations and report language as it relates to compounding pharmacy.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the NASEM report to the FDA on compounding bioidentical hormones. Issues related to the MOU under 503A of the FDCA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the federal regulation of compounding pharmacy. No specific legislation at this time.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
4th Quarter, 2020
Rock & Associates amended a lobbying report for representation of Women's International Pharmacy in Q42020 on Feb. 9, 2021.
Original Filing: 301248014.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Budget/Appropriations Health Issues Pharmacy
4th Quarter, 2020
In Q4, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Jan. 29, 2021.
Original Filing: 301247205.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Budget/Appropriations Health Issues Pharmacy
3rd Quarter, 2020
In Q3, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Oct. 14, 2020.
Original Filing: 301210081.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Budget/Appropriations Health Issues Pharmacy
2nd Quarter, 2020
In Q2, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Aug. 26, 2020.
Original Filing: 301205841.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Budget/Appropriations Health Issues Pharmacy
2nd Quarter, 2020
In Q2, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Aug. 26, 2020.
Original Filing: 301205843.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Budget/Appropriations Health Issues Pharmacy
1st Quarter, 2020
In Q1, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on June 6, 2020.
Original Filing: 301184236.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Budget/Appropriations Health Issues Pharmacy
4th Quarter, 2019
In Q4, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Jan. 26, 2020.
Original Filing: 301130453.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Budget/Appropriations Health Issues Pharmacy
3rd Quarter, 2019
In Q3, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Oct. 19, 2019.
Original Filing: 301072181.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Budget/Appropriations Health Issues Pharmacy
2nd Quarter, 2019
In Q2, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on July 17, 2019.
Original Filing: 301048181.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Budget/Appropriations Health Issues Pharmacy
1st Quarter, 2019
In Q1, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on April 18, 2019.
Original Filing: 301029582.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Budget/Appropriations Health Issues Pharmacy
4th Quarter, 2018
In Q4, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Jan. 17, 2019.
Original Filing: 301006622.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations; H.R. 1625, Consolidated Appropriations Act, 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
3rd Quarter, 2018
In Q3, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Oct. 14, 2018.
Original Filing: 300985072.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations; H.R. 1625, Consolidated Appropriations Act, 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
2nd Quarter, 2018
In Q2, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on July 18, 2018.
Original Filing: 300968466.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations; H.R. 1625, Consolidated Appropriations Act, 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
1st Quarter, 2018
In Q1, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on April 19, 2018.
Original Filing: 300951936.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations; H.R. 1625, Consolidated Appropriations Act, 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2017
In Q4, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Jan. 17, 2018.
Original Filing: 300925205.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2017
In Q3, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Oct. 18, 2017.
Original Filing: 300906922.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2017
In Q2, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on July 15, 2017.
Original Filing: 300885205.xml
Lobbying Issues
Appropriations to fund the FDA Implementation of compounding pharmacy regulations. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2017
In Q1, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on April 17, 2017.
Original Filing: 300866009.xml
Lobbying Issues
Appropriations to fund the FDA Implementation of compounding pharmacy regulations. No specific legislation introduced yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2016
In Q4, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Jan. 13, 2017.
Original Filing: 300845846.xml
Lobbying Issues
Appropriations (H.R. 5054 and S. 2956) to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2016
In Q3, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Oct. 11, 2016.
Original Filing: 300826238.xml
Lobbying Issues
Appropriations (H.R. 5054 and S. 2956) to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2016
In Q2, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on July 8, 2016.
Original Filing: 300807565.xml
Lobbying Issues
Appropriations (H.R. 5054 and S. 2956) to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2016
In Q1, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on April 12, 2016.
Original Filing: 300790095.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2015
In Q4, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Jan. 11, 2016.
Original Filing: 300770415.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2015
In Q3, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Oct. 13, 2015.
Original Filing: 300752250.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2015
In Q2, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on July 13, 2015.
Original Filing: 300733623.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2015
In Q1, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on April 7, 2015.
Original Filing: 300713073.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
4th Quarter, 2014
In Q4, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Jan. 13, 2015.
Original Filing: 300694790.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations. H.R. 4800 and S. 2437.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of dispense to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
3rd Quarter, 2014
In Q3, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Oct. 9, 2014.
Original Filing: 300674879.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations. H.R. 4800 and S.2437.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
2nd Quarter, 2014
In Q2, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on July 15, 2014.
Original Filing: 300656684.xml
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations. H.R. 4800 and S.2437.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
1st Quarter, 2014
In Q1, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on April 15, 2014.
Original Filing: 300635928.xml
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Appropriations to fund the FDA implimentation of compounding pharmacy regulations. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2013
In Q4, Rock & Associates lobbied for Women's International Pharmacy , earning $11,250. The report was filed on Jan. 13, 2014.
Original Filing: 300613201.xml
Lobbying Issues
S.959, H.R. 3089 & H.R. 3204, legislation affecting the operation of compounding pharmacies and the availability of compounded medications.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Medical/Disease Research/Clinical Labs Pharmacy
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
3rd Quarter, 2013
In Q3, Rock & Associates lobbied for Women's International Pharmacy , earning $11,200. The report was filed on Oct. 8, 2013.
Original Filing: 300591480.xml
Lobbying Issues
S.959, H.R. 3089 & H.R. 3204, legislation affecting the operation of compounding pharmacies and the availability of compounded medications.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Medical/Disease Research/Clinical Labs Pharmacy
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
2nd Quarter, 2013
In Q2, Rock & Associates lobbied for Women's International Pharmacy , earning $9,375. The report was filed on July 15, 2013.
Original Filing: 300572337.xml
Lobbying Issues
S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Medical/Disease Research/Clinical Labs Pharmacy
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
2nd Quarter, 2013
Rock & Associates filed a lobbying registration on May 14, 2013 to represent Women's International Pharmacy, effective April 16, 2013.
Original Filing: 300567428.xml
Issue(s) they said they’d lobby about: Issues related to the operation of compounding pharmacies and the availability of compounded medications. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate